GSE172494 3 V 1 NICOTINAMIDE HUMAN DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE172494 3 V 1 NICOTINAMIDE HUMAN DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE172494 3 V 1 NICOTINAMIDE HUMAN DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE172494 3 V 1 NICOTINAMIDE HUMAN DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE172494 3 V 1 NICOTINAMIDE HUMAN DN.

Results found

Linked to

 

Label

Description

 

Gene

H3 clustered histone 7

Gene

H2A clustered histone 11

Gene

notch 2 N-terminal like R

Gene

SPATA31 subfamily C member 2

Gene

SPATA31 subfamily C member 1

Gene

family with sequence similarity 240 member C

Gene

transmembrane and death domain 1

Gene

olfactory receptor family 4 subfamily N member 4C

Gene

aldehyde dehydrogenase 1 family member L1

Gene

solute carrier family 9 member A5

  • Gene

    H3 clustered histone 7


  • Gene

    H2A clustered histone 11


  • Gene

    notch 2 N-terminal like R


  • Gene

    SPATA31 subfamily C member 2


  • Gene

    SPATA31 subfamily C member 1


  • Gene

    family with sequence similarity 240 member C


  • Gene

    transmembrane and death domain 1


  • Gene

    olfactory receptor family 4 subfamily N member 4C


  • Gene

    aldehyde dehydrogenase 1 family member L1


  • Gene

    solute carrier family 9 member A5

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.